Vaxart (VXRT) 10-Q 8 Aug 24 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 01, 2024
Document Information [Line Items]
Entity Central Index Key	0000072444
Entity Registrant Name	Vaxart, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-35285
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	59-1212264
Entity Address, Address Line One	170 Harbor Way, Suite 300
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	550-3500
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	VXRT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		227,439,293

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 43,285	$ 34,755
Short-term investments	19,308	4,958
Accounts receivable	1,088	3,008
Unbilled receivable from government contracts	3,689	0
Prepaid expenses and other current assets	4,165	2,815
Total current assets	71,535	45,536
Property and equipment, net	10,280	11,731
Right-of-use assets, net	22,652	24,840
Intangible assets, net	3,923	4,289
Goodwill	4,508	4,508
Other long-term assets	851	926
Total assets	113,749	91,830
Current liabilities:
Accounts payable	3,587	1,584
Other accrued current liabilities	6,611	5,634
Current portion of operating lease liability	2,872	2,703
Current portion of liability related to sale of future royalties	2,686	3,803
Total current liabilities	15,756	13,724
Operating lease liability, net of current portion	15,983	17,385
Liability related to sale of future royalties, net of current portion	1,591	2,623
Other long-term liabilities	405	293
Total liabilities	33,735	34,025
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of June 30, 2024 and December 31, 2023	0	0
Common stock: $0.0001 par value; 350,000,000 shares authorized as of June 30, 2024 and 250,000,000 shares authorized as of December 31, 2023; 228,119,936 shares issued and 227,431,605 shares outstanding as of June 30, 2024 and 153,959,853 shares issued and 153,452,833 shares outstanding as of December 31, 2023	23	15
Additional paid-in capital	531,029	467,731
Treasury stock at cost, 688,331 shares as of June 30, 2024 and 507,020 shares as of December 31, 2023	(565)	(366)
Accumulated deficit	(450,457)	(409,574)
Accumulated other comprehensive loss	(16)	(1)
Total stockholders’ equity	80,014	57,805
Total liabilities and stockholders’ equity	$ 113,749	$ 91,830

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	350,000,000	250,000,000
Common stock, shares issued (in shares)	228,119,936	153,959,853
Common stock, shares outstanding (in shares)	227,431,605	153,452,833
Treasury Stock, Common, Shares (in shares)	688,331	507,020

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues	$ 6,401	$ 1,358	$ 8,582	$ 2,033
Operating expenses:
Research and development	17,480	18,813	36,493	38,435
General and administrative	5,177	5,598	12,415	12,223
Total operating expenses	22,657	24,411	48,908	50,658
Operating loss	(16,256)	(23,053)	(40,326)	(48,625)
Other income (expense):
Interest income	416	711	919	1,353
Non-cash interest expense related to sale of future royalties	(610)	(188)	(1,414)	(366)
Other income (expense), net	5	(1)	4	(4)
Loss before income taxes	(16,445)	(22,531)	(40,817)	(47,642)
Provision for income taxes	21	19	66	48
Net loss	$ (16,466)	$ (22,550)	$ (40,883)	$ (47,690)
Net loss per share - basic and diluted (in dollars per share)	$ (0.09)	$ (0.16)	$ (0.23)	$ (0.35)
Shares used to compute net loss per share - basic and diluted (in shares)	184,703,003	139,594,238	176,757,049	137,403,416
Comprehensive loss:
Net loss	$ (16,466)	$ (22,550)	$ (40,883)	$ (47,690)
Unrealized (loss) gain on available-for-sale investments, net of tax	(6)	46	(15)	275
Comprehensive loss	(16,472)	(22,504)	(40,898)	(47,415)
Non Cash Royalty Revenue [Member]
Revenues	37	30	622	308
Government Contract [Member]
Revenues	6,364	0	7,960	0
Grant [Member]
Revenues	$ 0	$ 1,328	$ 0	$ 1,725

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	The 2023 Shelf Registration [Member] Common Stock Outstanding [Member]	The 2023 Shelf Registration [Member] Treasury Stock, Common [Member]	The 2023 Shelf Registration [Member] Additional Paid-in Capital [Member]	The 2023 Shelf Registration [Member] Retained Earnings [Member]	The 2023 Shelf Registration [Member] AOCI Attributable to Parent [Member]	The 2023 Shelf Registration [Member]	September 2021 ATM [Member] Common Stock Outstanding [Member]	September 2021 ATM [Member] Treasury Stock, Common [Member]	September 2021 ATM [Member] Additional Paid-in Capital [Member]	September 2021 ATM [Member] Retained Earnings [Member]	September 2021 ATM [Member]	RA Capital Healthcare Fund 2024 [Member] Common Stock Outstanding [Member]	RA Capital Healthcare Fund 2024 [Member] Treasury Stock, Common [Member]	RA Capital Healthcare Fund 2024 [Member] Additional Paid-in Capital [Member]	RA Capital Healthcare Fund 2024 [Member] Retained Earnings [Member]	RA Capital Healthcare Fund 2024 [Member]	June 2024 Offering [Member] Common Stock Outstanding [Member]	June 2024 Offering [Member] Treasury Stock, Common [Member]	June 2024 Offering [Member] Additional Paid-in Capital [Member]	June 2024 Offering [Member] Retained Earnings [Member]	June 2024 Offering [Member]	Common Stock Outstanding [Member]	Treasury Stock, Common [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares)																						134,199,429	0
Balances (in shares) at Dec. 31, 2022																						134,199,429	0
Balances at Dec. 31, 2022																						$ 13	$ 0	$ 437,992	$ (327,109)	$ (299)	$ 110,597
Issuance of common stock (in shares)	16,000,000						1,362,220	0
Issuance of common stock	$ 1		$ 13,602			$ 13,603	$ 1	$ 0	$ 1,429	$ 0	$ 1,430
Issuance of common stock upon exercise of stock options (in shares)																						54,720	0				54,720
Issuance of common stock upon exercise of stock options																						$ 0	$ 0	17	0	0	$ 17
Issuance of common stock under ESPP (in shares)																						301,061	0
Issuance of common stock under ESPP																						$ 0	$ 0	298	0	0	298
Release of common stock for vested restricted stock units (in shares)																						98,808	0
Release of common stock for vested restricted stock units																						$ 0	$ 0	0	0	0	0
Repurchase of common stock to satisfy tax withholding (in shares)																						0	(33,246)
Repurchase of common stock to satisfy tax withholding																						$ 0	$ (31)	0	0	0	(31)
Stock-based compensation																						0	0	6,574		0	6,574
Unrealized gain on available-for-sale investments																						0	0	0	0	275	275
Net loss																						0	0	0	(47,690)	0	(47,690)
Balances at Jun. 30, 2023																						$ 15	$ (31)	459,912	(374,799)	(24)	85,073
Balances (in shares)																						135,610,869	(13,553)
Balances (in shares) at Mar. 31, 2023																						135,610,869	(13,553)
Balances at Mar. 31, 2023																						$ 14	$ (10)	442,068	(352,249)	(70)	89,753
Issuance of common stock (in shares)	16,000,000	0
Issuance of common stock	$ 1	$ 0	$ 13,602	$ 0		$ 13,603
Issuance of common stock upon exercise of stock options (in shares)																						54,720	0
Issuance of common stock upon exercise of stock options																						$ 0	$ 0	17	0	0	17
Issuance of common stock under ESPP (in shares)																						301,061	0
Issuance of common stock under ESPP																						$ 0	$ 0	298	0	0	298
Release of common stock for vested restricted stock units (in shares)																						49,588	0
Release of common stock for vested restricted stock units																						$ 0	$ 0	0	0	0	0
Repurchase of common stock to satisfy tax withholding (in shares)																							(19,693)
Repurchase of common stock to satisfy tax withholding																							$ (21)	0	0	0	(21)
Stock-based compensation																						0	0	3,927		0	3,927
Unrealized gain on available-for-sale investments																						0	0	0	0	46	46
Net loss																						0	0	0	(22,550)	0	(22,550)
Balances at Jun. 30, 2023																						$ 15	$ (31)	459,912	(374,799)	(24)	85,073
Balances (in shares)																						152,016,238	(33,246)
Balances (in shares)																						153,959,853	(507,020)
Balances (in shares) at Dec. 31, 2023																						153,959,853	(507,020)
Balances at Dec. 31, 2023																						$ 15	$ (366)	467,731	(409,574)	(1)	$ 57,805
Issuance of common stock (in shares)							7,719,641	0				15,384,615	0				50,000,000	0
Issuance of common stock							$ 1	$ 0	8,801	0	8,802	$ 2	$ 0	$ 9,943	$ 0	$ 9,945	$ 5	$ 0	$ 37,550	$ 0	$ 37,555
Issuance of common stock upon exercise of stock options (in shares)																						26,980	0				26,980
Issuance of common stock upon exercise of stock options																						$ 0	$ 0	21	0	0	$ 21
Issuance of common stock under ESPP (in shares)																						502,423	0
Issuance of common stock under ESPP																						$ 0	$ 0	312	0	0	312
Release of common stock for vested restricted stock units (in shares)																						526,424	0
Release of common stock for vested restricted stock units																						$ 0	$ 0	0	0	0	0
Repurchase of common stock to satisfy tax withholding (in shares)																						0	(181,311)
Repurchase of common stock to satisfy tax withholding																						$ 0	$ (199)	0	0	0	(199)
Stock-based compensation																						0	0	6,671		0	6,671
Unrealized gain on available-for-sale investments																						0	0	0	0	(15)	(15)
Net loss																						0	0	0	(40,883)	0	(40,883)
Balances at Jun. 30, 2024																						$ 23	$ (565)	531,029	(450,457)	(16)	80,014
Balances (in shares)																						177,187,965	(664,923)
Balances (in shares) at Mar. 31, 2024																						177,187,965	(664,923)
Balances at Mar. 31, 2024																						$ 18	$ (548)	490,221	(433,991)	(10)	55,690
Issuance of common stock (in shares)							314,969	0				0	0				50,000,000	0
Issuance of common stock							$ 0	$ 0	$ 377	$ 0	$ 377	$ 0	$ 0	$ 0	$ 0	$ 0	$ 5	$ 0	$ 37,550	$ 0	$ 37,555
Issuance of common stock upon exercise of stock options (in shares)																						18,115	0
Issuance of common stock upon exercise of stock options																						$ 0	$ 0	14	0	0	14
Issuance of common stock under ESPP (in shares)																						502,423	0
Issuance of common stock under ESPP																						$ 0	$ 0	312	0	0	312
Release of common stock for vested restricted stock units (in shares)																						96,464	0
Release of common stock for vested restricted stock units																						$ 0	$ 0	0	0	0	0
Repurchase of common stock to satisfy tax withholding (in shares)																						0	(23,408)
Repurchase of common stock to satisfy tax withholding																						$ 0	$ (17)	0	0	0	(17)
Stock-based compensation																						0	0	2,555		0	2,555
Unrealized gain on available-for-sale investments																						0	0	0	0	(6)	(6)
Net loss																						0	0	0	(16,466)	0	(16,466)
Balances at Jun. 30, 2024																						$ 23	$ (565)	$ 531,029	$ (450,457)	$ (16)	$ 80,014
Balances (in shares)																						228,119,936	(688,331)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023
The 2023 Shelf Registration [Member]
Offering costs			$ 284
September 2021 ATM [Member]
Offering costs	$ 21	$ 248	$ 103
RA Capital Healthcare Fund 2024 [Member]
Offering costs	55	55
June 2024 Offering [Member]
Offering costs	$ 2,445	$ 2,445

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (40,883,000)	$ (47,690,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,390,000	4,228,000
Amortization of discount on investments, net	(178,000)	(220,000)
Stock-based compensation	6,671,000	6,574,000
Non-cash interest expense related to sale of future royalties	1,414,000	366,000
Non-cash revenue related to sale of future royalties	(3,563,000)	(288,000)
Change in operating assets and liabilities:
Accounts receivable	1,920,000	(9,000)
Unbilled receivable from government contracts	(3,689,000)	0
Prepaid expenses and other assets	(1,275,000)	2,447,000
Accounts payable	2,083,000	105,000
Deferred grant revenue	0	(1,725,000)
Other accrued liabilities	(108,000)	(5,723,000)
Net cash used in operating activities	(33,218,000)	(41,931,000)
Cash flows from investing activities:
Purchases of property and equipment	(501,000)	(1,693,000)
Purchases of investments	(29,187,000)	(22,629,000)
Proceeds from maturities of investments	15,000,000	48,200,000
Net cash (used in) provided by investing activities	(14,688,000)	23,878,000
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of stock options	21,000	17,000
Shares acquired to settle employee tax withholding liabilities	(199,000)	(31,000)
Proceeds from issuance of common stock under the employee stock purchase plan	312,000	298,000
Net cash provided by financing activities	56,436,000	15,317,000
Net increase (decrease) in cash, cash equivalents and restricted cash	8,530,000	(2,736,000)
Cash, cash equivalents and restricted cash at beginning of the period	34,755,000	46,013,000
Cash, cash equivalents and restricted cash at end of the period	43,285,000	43,277,000
Supplemental reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets:
Restricted cash	0	275,000
Cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows at the end of the period	43,285,000	43,277,000
Supplemental disclosure of non-cash investing and financing activity:
Operating lease liabilities arising from obtaining right-of-use assets	0	296,000
Acquisition of property and equipment included in accounts payable and accrued expenses	35,000	281,000
June 2024 Offering [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock	37,555,000	0
Registered Direct Offering [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock	0	13,603,000
At-the-market Facility [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock	8,802,000	1,430,000
RA Capital Healthcare Fund 2024 [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock	$ 9,945,000	$ 0

Note 1 - Organization and Natur

Note 1 - Organization and Nature of Business	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. General Vaxart Biosciences, Inc. was originally incorporated in California in March 2004, July 2007, February 2018, In June 2024, In January 2024, “2024 3 No. 333 270671 “2023 2024 In September 2021, “September 2021 may September 16, 2021, May 9, 2023 six June 30, 2024, September 2021 June 30, 2024 , not September 2021 The Company’s principal operations are based in South San Francisco, California, and it operates in one

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Basis of Presentation, Liquidity and Going Concern The Company is a clinical-stage biotechnology company with no June 30, 2024, Based on management's current plan, the Company expects to have cash runway into 2026. no The condensed consolidated balance sheet as of December 31, 2023, not December 31, 2023, 10 March 14, 2024 ( no Note 2 not Basis of Consolidation Use of Estimates Concentration of Credit Risk The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one Revenue Recognition Revenue from Government Contracts Under firm fixed-price milestone contracts, the Company recognizes the firm fixed-price revenue as the milestones are substantially complete and the firm fixed-price for the milestone is earned (“firm fixed-price milestone”). Under cost reimbursable contracts, the Company recognizes revenue as allowable costs are incurred and the fixed fee is earned (“cost-plus-fixed-fee”). Reimbursable costs under the contract primarily include direct labor, subcontract costs, materials, equipment, travel, and approved overhead and indirect costs. Fixed fees under cost reimbursable contracts are earned in proportion to the allowable costs incurred in performance of the work relative to total estimated contract costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed. Payments to the Company under cost reimbursable contracts are provisional payments subject to adjustment upon annual audit by the government. Management believes that revenue for periods not may Recent Accounting Pronouncements The Company has reviewed all significant newly-issued accounting pronouncements that are not not not

Note 3 - Fair Value of Financia

Note 3 - Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3 . Fair Value of Financial Instruments Fair value accounting is applied for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued liabilities that approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three The three Level 1 Level 2 not Level 3 no The following table sets forth the fair value of the Company’s financial assets that are measured on a recurring basis as of June 30, 2024 December 31, 2023 Level 1 Level 2 Level 3 Total June 30, 2024 Financial assets: Money market funds $ 38,000 $ — $ — $ 38,000 U.S. Treasury securities — 19,308 — 19,308 Total assets $ 38,000 $ 19,308 $ — $ 57,308 Level 1 Level 2 Level 3 Total December 31, 2023 Financial assets: Money market funds $ 31,403 $ — $ — $ 31,403 U.S. Treasury securities — 4,958 — 4,958 Total assets $ 31,403 $ 4,958 $ — $ 36,361 The Company held no financial liabilities measured on a recurring basis as of June 30, 2024 December 31, 2023

Note 4 - Balance Sheet Componen

Note 4 - Balance Sheet Components	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	NOTE 4 . Balance Sheet Components (a) Cash, Cash Equivalents a nd Investments Cash, cash equivalents and investments consisted of the following (in thousands): Amortized Gross Unrealized Estimated Cash and Cash Short-Term Cost Gains Losses Fair Value Equivalents Investments June 30, 2024 Cash at banks $ 5,285 $ — $ — $ 5,285 $ 5,285 $ — Money market funds 38,000 — — 38,000 38,000 — U.S. Treasury securities 19,324 — (16 ) 19,308 — 19,308 Total $ 62,609 $ — $ (16 ) $ 62,593 $ 43,285 $ 19,308 Amortized Gross Unrealized Estimated Cash and Cash Short-Term Cost Gains Losses Fair Value Equivalents Investments December 31, 2023 Cash at banks $ 3,352 $ — $ — $ 3,352 $ 3,352 $ — Money market funds 31,403 — — 31,403 31,403 — U.S. Treasury securities 4,959 — (1 ) 4,958 — 4,958 Total $ 39,714 $ — $ (1 ) $ 39,713 $ 34,755 $ 4,958 As of June 30, 2024 December 31, 2023, 12 (b) Accounts Receivable Accounts receivable consists of $1.053 million of government contract receivables from HHS BARDA, and $35,000 royalty receivable totaling $1.088 million as of June 30, 2024 December 31, 2023. An allowance for expected credit losses over the life of the receivables is reserved for based on a combination of historical experience, aging analysis, current economic trends and information on specific accounts, with related amounts recorded as a reserve against revenue recognized. The reserve is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. The Company has provided no allowance for credit losses as of June 30, 2024 December 31, 2023. (c) Unbilled Receivable from Government Contracts Unbilled receivable which was earned and not June 30, 2024 December 31, 2023, (d) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consists of the following (in thousands): June 30, 2024 December 31, 2023 Prepaid clinical and manufacturing expenses $ 2,218 $ 984 Prepaid insurance 734 258 Prepaid rent — 488 Other prepaid 885 752 Other current assets 328 333 Prepaid expenses and other current assets $ 4,165 $ 2,815 (e) Property and Equipment, Net Property and equipment, net consists of the following (in thousands): June 30, 2024 December 31, 2023 Laboratory equipment $ 13,554 $ 13,448 Office and computer equipment 1,120 1,105 Leasehold improvements 4,078 3,985 Construction in progress 191 24 Total property and equipment 18,943 18,562 Less: accumulated depreciation (8,663 ) (6,831 ) Property and equipment, net $ 10,280 $ 11,731 Depreciation expense was $0.9 million for each of the three June 30, 2024 2023 six June 30, 2024 2023. three six June 30, 2024 2023. (f) Right-of-Use Assets , Net Right-of-use assets, net comprises facilities of $22.7 million and $24.8 million as of June 30, 2024 December 31, 2023 2023, December 31, 2023. (g) Intangible Assets, Net Intangible assets comprise developed technology and intellectual property. Intangible assets are carried at cost less accumulated amortization. As of June 30, 2024 June 30, 2024, no June 30, 2024 December 31, 2023 Developed technology $ 5,000 $ 5,000 Intellectual property 80 80 Total cost 5,080 5,080 Less: accumulated amortization (1,157 ) (791 ) Intangible assets, net $ 3,923 $ 4,289 Intangible asset amortization expense was $0.2 million for each of the three June 30, 2024 2023, six June 30, 2024 2023. As of June 30, 2024 Year Ending December 31, Amount 2024 (six months remaining) $ 365 2025 732 2026 731 2027 731 2028 727 Thereafter 637 Total $ 3,923 (h) Goodwill Goodwill, which represents the excess of the purchase price over the fair value of assets acquired, comprises $4.5 June 30, 2024 December 31, 2023 June 30, 2024 no (i) Other Accrued Current Liabilities Other accrued current liabilities consist of the following (in thousands): June 30, 2024 December 31, 2023 Accrued compensation $ 3,704 $ 4,576 Accrued clinical and manufacturing expenses 1,591 312 Accrued professional and consulting services 522 211 Other liabilities, current portion 794 535 Total $ 6,611 $ 5,634

Note 5 - Revenue

Note 5 - Revenue	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Revenue [Text Block]	NOTE 5 . Revenue Royalty Revenue Related to Sale of Future Royalties The Company generates royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen entered into with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) in 2009. September 2010, August 2036, first fourth six June 30, 2024 2023 three June 30, 2024 2023 six June 30, 2024 2023, three June 30, 2024 2023 six June 30, 2024 2023, Note 6 Revenue from Government Contracts The Company recognized revenue from government contracts of $6.4 million and $8.0 million for the three six June 30, 2024, 2024 2024 not June 30, 2024, 2024 In June 2024, “2024 2024 2b 19 2024 2024 2b 2024 958 605 2024 2024 2024 three six June 30, 2024, 2024 Management believes that if the 2024 2b not may 2024 In January 2024, “2024 2024 2b 2024 July 2024, July 2024 October 2024. 2024 958 605 2024 three six June 30, 2024, 2024 Grant Revenue In November 2022, July 2023 three June 30, 2024 2023, six June 30, 2024 2023, December 31, 2023.

Note 6 - Liabilities Related to

Note 6 - Liabilities Related to Sale of Future Royalties	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Liabilities Related to Sale of Future Royalties [Text Block]	6 . Liabilities Related to Sale of Future Royalties In April 2016, first April 1, 2016 March 31, 2025, first April 1, second April 1, 2025 December 24, 2029, first March 31 st first April 1, 2016 March 31, 2025, second April 1, 2025 December 24, 2029, April 1, 2028 December 24, 2029. December 24, 2029, For avoidance of doubt, the RIAA states, in the event there is a remaining cumulative remaining shortfall amount as of December 24, 2029, not June 30, 2024 December 31, 2023, Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the RIAA, this transaction was accounted for as a liability that is being amortized using the effective interest method over the life of the arrangement. The Company has no not not The following table shows the activity within the liability account during the six June 30, 2024 Total liability related to sale of future royalties, start of period $ 6,426 Non-cash royalty revenue paid to HCRP (3,563 ) Non-cash interest expense recognized 1,414 Total liability related to sale of future royalties, end of period 4,277 Current portion (2,686 ) Long-term portion $ 1,591

Note 7 - Leases

Note 7 - Leases	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7 . Leas es The Company has obtained the right of use for office and manufacturing facilities under six one In September 2021, March 31, 2029. two one third 2022 first 2023, As of June 30, 2024 one The following table summarizes the Company’s undiscounted cash payment obligations for its operating lease liabilities with initial terms of more than 12 June 30, 2024 Year Ending December 31, 2024 (six months remaining) $ 2,209 2025 4,511 2026 5,031 2027 5,207 2028 5,389 Thereafter 1,348 Undiscounted total 23,695 Less: imputed interest (4,840 ) Present value of future minimum payments 18,855 Current portion of operating lease liability (2,872 ) Operating lease liability, net of current portion $ 15,983 The Company is also required to pay for operating expenses related to the leased space. The operating expenses are incurred separately and were not three six June 30, 2024 2023, Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Lease cost Operating lease cost $ 1,553 $ 1,553 $ 3,107 $ 3,063 Short-term lease cost 7 10 19 31 Variable lease cost 381 431 885 942 Sublease income (20 ) — (34 ) - Total lease cost $ 1,921 $ 1,994 $ 3,977 $ 4,036

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8 . Commitments and Contingencies (a) Purchase Commitments As of June 30, 2024 Note 7 (b) Indemnifications In the ordinary course of business, the Company enters into agreements that may may third not may may (c) From time to time the Company may In August September 2020, two first Himmelberg v. Vaxart, Inc. et al. August 24, 2020. second Hovhannisyan v. Vaxart, Inc. et al. September 1, 2020 ( September 17, 2020, two December 9, 2020, On January 29, 2021, July 8, 2021, May 14, 2021, June 10, 2021, first August 9, 2021, first first three 10 10b 5, 20 20A first first July 8, 2021, first December 22, 2021, July 27, 2022, $2.0 November 2, 2022, November 14, 2022, second January 25, 2023, On October 23, 2020, Roth v. Armistice Capital LLC, et al. 16 March 27, 2024, April 11, 2024, June 2024, July 2024, On January 8, 2021, pro se Chan v. Vaxart, Inc. et al.

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Equity [Text Block]	9 . Stock holders’ Equity (a) P referred Stock The Company is authorized to issue 5,000,000 shares of preferred stock, $0.0001 par value per share. The Company’s board of directors may, 5,000,000 one may no (b) As of June 30, 2024, June 11, 2024, one may no June 30, 2024 In June 2024, In January 2024, 2024 2023 2024 In the event of the Company’s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all the Company’s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied. There are no The Company had shares of common stock reserved for issuance as follows: June 30, 2024 December 31, 2023 Options issued and outstanding 21,699,803 17,938,726 RSUs issued and outstanding 3,135,958 2,126,373 2019 Equity Incentive Plan available for future grant 16,621,469 5,685,806 2024 Inducement Award Plan available for future grant 1,727,500 — Common stock warrants 140,596 227,434 2022 Employee Stock Purchase Plan 2,362,902 1,065,325 Total 45,688,228 27,043,664 The approved increase of reserved common stock for 2019 2022 Note 10 (c) Treasury Stock The Company generally withholds shares of its common stock to cover employees' portion of required tax withholdings when employee equity awards are issued or vest. These shares are valued at cost, which equals the market price of the common stock on the date of issuance or vesting. The Company had 688,331 and 507,020 treasury shares as of June 30, 2024 December 31, 2023, (d) Warrants In April 2024, March 31, 2024, June 30, 2024 none Securities into which warrants are convertible Warrants Outstanding Exercise Price Expiration Date Common Stock 29,150 $ 2.50 March 2025 Common Stock 100,532 $ 3.125 February 2025 Common Stock 10,914 $ 22.99 December 2026 Total 140,596 In the event of a Fundamental Transaction (a transfer of ownership of the Company as defined in the warrant) within the Company’s control, the holders of the unexercised common stock warrants exercisable for $2.50 and those exercisable for $3.125 shall be entitled to receive cash consideration equal to a Black-Scholes valuation, as defined in the warrant. If such Fundamental Transaction is not

Note 10 - Equity Incentive Plan

Note 10 - Equity Incentive Plans	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	NOTE 1 0 . Equity Incentive Plan s On April 23, 2019, 2019 “2019 may 2019 may 2019 not 2019 The aggregate number of shares of common stock authorized for issuance under the 2019 2019 June 8, 2020, June 16, 2021, August 4, 2022, June 11, 2024, 2019 2019 ten may On February 27, 2024, 2024 “2024 2024 5635 4 2024 2024 2019 may not 2024 2024 may A summary of stock option and RSU transactions in the six June 30, 2024 Weighted Weighted Shares Number of Option Average Unvested RSU Average Available Options Exercise RSU Shares Grant Date For Grant Outstanding Price Outstanding Fair Value Balance as of January 1, 2024 5,685,806 17,938,726 $ 2.90 2,126,373 $ 1.37 Authorized under 2024 Inducement Plan 3,000,000 Authorized under 2019 Plan 15,000,000 Granted (7,135,230 ) 5,226,937 $ 1.12 1,908,293 $ 1.14 Exercised (26,980 ) $ 0.78 Released (526,424 ) $ 1.39 Forfeited 1,659,141 (1,286,857 ) $ 2.20 (372,284 ) $ 1.49 Canceled 139,252 (152,023 ) $ 5.20 Balance as of June 30, 2024 18,348,969 21,699,803 $ 2.50 3,135,958 $ 1.21 As of June 30, 2024 The Company received $21,000 for the 26,980 options exercised during the six June 30, 2024 six June 30, 2023, June 30, 2024 June 28, 2024, The weighted average grant date fair value of options awarded in the six June 30, 2024 2023 Six Months Ended June 30, 2024 2023 Risk-free interest rate 4.4 % 3.5% - 3.9 % Expected term (in years) 6.00 6.00 Expected volatility 128.9% - 129.3 % 127.8% - 129.5 % Dividend yield — % — % The Company measures the fair value of all stock-based awards on the grant date and records the fair value of these awards, net of estimated forfeitures, to compensation expense over the service period. Total stock-based compensation recognized for options, RSUs and ESPP was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Research and development $ 1,868 $ 2,366 $ 3,675 $ 3,738 General and administrative 687 1,561 2,996 2,836 Total stock-based compensation $ 2,555 $ 3,927 $ 6,671 $ 6,574 As of June 30, 2024 On August 4, 2022, 2022 “2022 2022 2022 June 11, 2024, 2022 six one May 2024, 2022 one six May 31, 2024, July 1, 2024 five 85% six six June 30, 2024 2022 June 30, 2024, 2022 The estimated fair value used for the six December 1, 2023 May 31, 2024, six June 1, 2023 November 30, 2023 six December 1, 2022 May 31, 2023 June 30, 2024, one July 1, 2024. 2022 Six-Month Offering Period Ending May 31, Six-Month Offering Period Ending Nov 30, Six-Month Offering Period Ending May 31, 2024 2023 2023 Risk-free interest rate 5.3 % 5.4 % 4.6 % Expected term (in years) 0.50 0.50 0.50 Expected volatility 75.2 % 98.6 % 84.7 % Dividend yield — % — % — %

Note 11 - Net Loss Per Share At

Note 11 - Net Loss Per Share Attributable to Common Stockholders	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 11 . Net Loss Per Share Attributable to Common Stockholders The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net loss $ (16,466 ) $ (22,550 ) $ (40,883 ) $ (47,690 ) Shares used to compute net loss per share – basic and diluted 184,703,003 139,594,238 176,757,049 137,403,416 Net loss per share – basic and diluted $ (0.09 ) $ (0.16 ) $ (0.23 ) $ (0.35 ) No three six June 30, 2024 2023 The following potentially dilutive weighted average securities were excluded from the computation of weighted average shares outstanding because they would have been antidilutive: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Options to purchase common stock 21,705,187 18,469,856 19,869,813 16,452,951 Restricted stock units to purchase common stock 3,223,944 3,672,594 2,600,499 2,445,397 Warrants to purchase common stock 140,596 227,434 175,928 227,434 Employee Stock Purchase Plan — 368,335 235,819 400,832 Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation 25,069,727 22,738,219 22,882,059 19,526,614

Note 12 - Subsequent Events

Note 12 - Subsequent Events	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	N ote 12. On July 2, 2024, not $1.00 5550 2 The Notice does not The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 30 May 17, 2024 July 1, 2024, no The Company intends to actively monitor the closing bid price of its common stock and is considering its options to regain compliance with the Bid Price Requirement. There can be no

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		5 . Other Information During the quarter ended June 30, 2024, no 16a 1 10b5 1 10b5 1 408
Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation, Liquidity and Going Concern The Company is a clinical-stage biotechnology company with no June 30, 2024, Based on management's current plan, the Company expects to have cash runway into 2026. no The condensed consolidated balance sheet as of December 31, 2023, not December 31, 2023, 10 March 14, 2024 ( no Note 2 not
Consolidation, Policy [Policy Text Block]	Basis of Consolidation
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one
Revenue [Policy Text Block]	Revenue Recognition Revenue from Government Contracts Under firm fixed-price milestone contracts, the Company recognizes the firm fixed-price revenue as the milestones are substantially complete and the firm fixed-price for the milestone is earned (“firm fixed-price milestone”). Under cost reimbursable contracts, the Company recognizes revenue as allowable costs are incurred and the fixed fee is earned (“cost-plus-fixed-fee”). Reimbursable costs under the contract primarily include direct labor, subcontract costs, materials, equipment, travel, and approved overhead and indirect costs. Fixed fees under cost reimbursable contracts are earned in proportion to the allowable costs incurred in performance of the work relative to total estimated contract costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed. Payments to the Company under cost reimbursable contracts are provisional payments subject to adjustment upon annual audit by the government. Management believes that revenue for periods not may
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements The Company has reviewed all significant newly-issued accounting pronouncements that are not not not

Note 3 - Fair Value of Financ_2

Note 3 - Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Total June 30, 2024 Financial assets: Money market funds $ 38,000 $ — $ — $ 38,000 U.S. Treasury securities — 19,308 — 19,308 Total assets $ 38,000 $ 19,308 $ — $ 57,308 Level 1 Level 2 Level 3 Total December 31, 2023 Financial assets: Money market funds $ 31,403 $ — $ — $ 31,403 U.S. Treasury securities — 4,958 — 4,958 Total assets $ 31,403 $ 4,958 $ — $ 36,361

Note 4 - Balance Sheet Compon_2

Note 4 - Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	Amortized Gross Unrealized Estimated Cash and Cash Short-Term Cost Gains Losses Fair Value Equivalents Investments June 30, 2024 Cash at banks $ 5,285 $ — $ — $ 5,285 $ 5,285 $ — Money market funds 38,000 — — 38,000 38,000 — U.S. Treasury securities 19,324 — (16 ) 19,308 — 19,308 Total $ 62,609 $ — $ (16 ) $ 62,593 $ 43,285 $ 19,308 Amortized Gross Unrealized Estimated Cash and Cash Short-Term Cost Gains Losses Fair Value Equivalents Investments December 31, 2023 Cash at banks $ 3,352 $ — $ — $ 3,352 $ 3,352 $ — Money market funds 31,403 — — 31,403 31,403 — U.S. Treasury securities 4,959 — (1 ) 4,958 — 4,958 Total $ 39,714 $ — $ (1 ) $ 39,713 $ 34,755 $ 4,958
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	June 30, 2024 December 31, 2023 Prepaid clinical and manufacturing expenses $ 2,218 $ 984 Prepaid insurance 734 258 Prepaid rent — 488 Other prepaid 885 752 Other current assets 328 333 Prepaid expenses and other current assets $ 4,165 $ 2,815
Property, Plant and Equipment [Table Text Block]	June 30, 2024 December 31, 2023 Laboratory equipment $ 13,554 $ 13,448 Office and computer equipment 1,120 1,105 Leasehold improvements 4,078 3,985 Construction in progress 191 24 Total property and equipment 18,943 18,562 Less: accumulated depreciation (8,663 ) (6,831 ) Property and equipment, net $ 10,280 $ 11,731
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, 2024 December 31, 2023 Developed technology $ 5,000 $ 5,000 Intellectual property 80 80 Total cost 5,080 5,080 Less: accumulated amortization (1,157 ) (791 ) Intangible assets, net $ 3,923 $ 4,289
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ending December 31, Amount 2024 (six months remaining) $ 365 2025 732 2026 731 2027 731 2028 727 Thereafter 637 Total $ 3,923
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2024 December 31, 2023 Accrued compensation $ 3,704 $ 4,576 Accrued clinical and manufacturing expenses 1,591 312 Accrued professional and consulting services 522 211 Other liabilities, current portion 794 535 Total $ 6,611 $ 5,634

Note 6 - Liabilities Related _2

Note 6 - Liabilities Related to Sale of Future Royalties (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Total liability related to sale of future royalties, start of period $ 6,426 Non-cash royalty revenue paid to HCRP (3,563 ) Non-cash interest expense recognized 1,414 Total liability related to sale of future royalties, end of period 4,277 Current portion (2,686 ) Long-term portion $ 1,591

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Year Ending December 31, 2024 (six months remaining) $ 2,209 2025 4,511 2026 5,031 2027 5,207 2028 5,389 Thereafter 1,348 Undiscounted total 23,695 Less: imputed interest (4,840 ) Present value of future minimum payments 18,855 Current portion of operating lease liability (2,872 ) Operating lease liability, net of current portion $ 15,983
Lease, Cost [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Lease cost Operating lease cost $ 1,553 $ 1,553 $ 3,107 $ 3,063 Short-term lease cost 7 10 19 31 Variable lease cost 381 431 885 942 Sublease income (20 ) — (34 ) - Total lease cost $ 1,921 $ 1,994 $ 3,977 $ 4,036

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Common Stock Reserved for Issuance [Table Text Block]	June 30, 2024 December 31, 2023 Options issued and outstanding 21,699,803 17,938,726 RSUs issued and outstanding 3,135,958 2,126,373 2019 Equity Incentive Plan available for future grant 16,621,469 5,685,806 2024 Inducement Award Plan available for future grant 1,727,500 — Common stock warrants 140,596 227,434 2022 Employee Stock Purchase Plan 2,362,902 1,065,325 Total 45,688,228 27,043,664
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Securities into which warrants are convertible Warrants Outstanding Exercise Price Expiration Date Common Stock 29,150 $ 2.50 March 2025 Common Stock 100,532 $ 3.125 February 2025 Common Stock 10,914 $ 22.99 December 2026 Total 140,596

Note 10 - Equity Incentive Pl_2

Note 10 - Equity Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Weighted Shares Number of Option Average Unvested RSU Average Available Options Exercise RSU Shares Grant Date For Grant Outstanding Price Outstanding Fair Value Balance as of January 1, 2024 5,685,806 17,938,726 $ 2.90 2,126,373 $ 1.37 Authorized under 2024 Inducement Plan 3,000,000 Authorized under 2019 Plan 15,000,000 Granted (7,135,230 ) 5,226,937 $ 1.12 1,908,293 $ 1.14 Exercised (26,980 ) $ 0.78 Released (526,424 ) $ 1.39 Forfeited 1,659,141 (1,286,857 ) $ 2.20 (372,284 ) $ 1.49 Canceled 139,252 (152,023 ) $ 5.20 Balance as of June 30, 2024 18,348,969 21,699,803 $ 2.50 3,135,958 $ 1.21
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Six Months Ended June 30, 2024 2023 Risk-free interest rate 4.4 % 3.5% - 3.9 % Expected term (in years) 6.00 6.00 Expected volatility 128.9% - 129.3 % 127.8% - 129.5 % Dividend yield — % — %
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Research and development $ 1,868 $ 2,366 $ 3,675 $ 3,738 General and administrative 687 1,561 2,996 2,836 Total stock-based compensation $ 2,555 $ 3,927 $ 6,671 $ 6,574
Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	Six-Month Offering Period Ending May 31, Six-Month Offering Period Ending Nov 30, Six-Month Offering Period Ending May 31, 2024 2023 2023 Risk-free interest rate 5.3 % 5.4 % 4.6 % Expected term (in years) 0.50 0.50 0.50 Expected volatility 75.2 % 98.6 % 84.7 % Dividend yield — % — % — %

Note 11 - Net Loss Per Share _2

Note 11 - Net Loss Per Share Attributable to Common Stockholders (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net loss $ (16,466 ) $ (22,550 ) $ (40,883 ) $ (47,690 ) Shares used to compute net loss per share – basic and diluted 184,703,003 139,594,238 176,757,049 137,403,416 Net loss per share – basic and diluted $ (0.09 ) $ (0.16 ) $ (0.23 ) $ (0.35 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Options to purchase common stock 21,705,187 18,469,856 19,869,813 16,452,951 Restricted stock units to purchase common stock 3,223,944 3,672,594 2,600,499 2,445,397 Warrants to purchase common stock 140,596 227,434 175,928 227,434 Employee Stock Purchase Plan — 368,335 235,819 400,832 Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation 25,069,727 22,738,219 22,882,059 19,526,614

Note 1 - Organization and Nat_2

Note 1 - Organization and Nature of Business (Details Textual) $ / shares in Units, $ in Thousands		1 Months Ended		6 Months Ended
	Sep. 15, 2021 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Jan. 31, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)
Number of Reportable Segments				1
June 2024 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares		50,000,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares		$ 0.8		$ 0.8
Proceeds from Issuance or Sale of Equity		$ 40,000
Proceeds from Issuance of Common Stock		$ 37,600		$ 37,555	$ 0
RA Capital Healthcare Fund 2024 [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares			15,384,615
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 0.65
Proceeds from Issuance of Common Stock			$ 9,900	$ 9,945	$ 0
Gross Proceeds from Issuance of Common Stock			$ 10,000
The September 2021 ATM [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares				7,719,641
Proceeds from Issuance or Sale of Equity				$ 9,100
Proceeds from Issuance of Common Stock				$ 8,800
Open Market Sale Agreement, Maximum Aggregate Offering Price	$ 100,000
Open Market Sale Agreement, Sales Commission, Percentage	3%

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Millions	Jun. 30, 2024 USD ($)
Cash, Cash Equivalents, and Short-Term Investments	$ 62.6

Note 3 - Fair Value of Financ_3

Note 3 - Fair Value of Financial Instruments (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Fair Value, Recurring [Member]
Financial Liabilities Fair Value Disclosure, Total	$ 0	$ 0

Note 3 - Fair Value of Financ_4

Note 3 - Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Money Market Funds [Member]
Money market funds, Fair Value	$ 38,000	$ 31,403
Fair Value, Recurring [Member]
Total assets	57,308	36,361
Fair Value, Recurring [Member] | US Treasury Securities [Member]
Investments, Fair Value Disclosure	19,308	4,958
Fair Value, Recurring [Member] | Money Market Funds [Member]
Money market funds, Fair Value	38,000	31,403
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Total assets	38,000	31,403
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Investments, Fair Value Disclosure	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Money market funds, Fair Value	38,000	31,403
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Total assets	19,308	4,958
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Investments, Fair Value Disclosure	19,308	4,958
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Money market funds, Fair Value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Total assets	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Investments, Fair Value Disclosure	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Money market funds, Fair Value	$ 0	$ 0

Note 4 - Balance Sheet Compon_3

Note 4 - Balance Sheet Components (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Accounts Receivable, after Allowance for Credit Loss	$ 1,088,000		$ 1,088,000
Accounts Receivable, Allowance for Credit Loss	0		0		$ 0
Unbilled Receivables, Current	3,689,000		3,689,000		0
Depreciation	900,000	$ 900,000	1,800,000	$ 1,800,000
Tangible Asset Impairment Charges	0	0	0	0
Operating Lease, Right-of-Use Asset	22,652,000		22,652,000		24,840,000
Amortization of Intangible Assets	200,000	$ 200,000	400,000	$ 400,000
Goodwill	4,508,000		4,508,000		4,508,000
Goodwill, Impairment Loss			$ 0
Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Remaining Life (Year)			5 years 4 months 24 days
Intellectual Property [Member]
Finite-Lived Intangible Asset, Remaining Life (Year)			3 years 6 months
Facility in Burlingame, California [Member]
Operating Lease, Right-of-Use Asset					3,100,000
BARDA [Member]
Unbilled Receivables, Current	3,700,000		$ 3,700,000		0
Government Contract [Member]
Accounts Receivable, after Allowance for Credit Loss	1,053,000		1,053,000
Royalty [Member]
Accounts Receivable, after Allowance for Credit Loss					$ 3,000,000
Prepaid Royalties	$ 35,000		$ 35,000

Note 4 - Balance Sheet Compon_4

Note 4 - Balance Sheet Components - Cash and Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Cash and cash equivalents	$ 43,285	$ 34,755	$ 43,277	$ 46,013
Gross Unrealized Loss	(16)	(1)
Short-term investments	19,308	4,958
Investments and Cash	62,609	39,714
Investments and Cash, Fair Value Disclosure	62,593	39,713
US Treasury Securities [Member]
Cash and cash equivalents	0
Amortized Cost	19,324	4,959
Gross Unrealized Loss	(16)	(1)
Estimated Fair Value	19,308	4,958
Short-term investments	19,308	4,958
Cash [Member]
Cash and Cash Equivalents, at Carrying Value	5,285	3,352
Money market funds, Fair Value	5,285	3,352
Cash and cash equivalents	5,285	3,352
Money Market Funds [Member]
Cash and Cash Equivalents, at Carrying Value	38,000	31,403
Money market funds, Fair Value	38,000	31,403
Cash and cash equivalents	$ 38,000	$ 31,403

Note 4 - Balance Sheet Compon_5

Note 4 - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Prepaid clinical and manufacturing expenses	$ 2,218	$ 984
Prepaid insurance	734	258
Prepaid rent	0	488
Other prepaid	885	752
Other current assets	328	333
Prepaid expenses and other current assets	$ 4,165	$ 2,815

Note 4 - Balance Sheet Compon_6

Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property and equipment, gross	$ 18,943	$ 18,562
Less: accumulated depreciation	(8,663)	(6,831)
Property and equipment, net	10,280	11,731
Laboratory Equipment [Member]
Property and equipment, gross	13,554	13,448
Office Equipment [Member]
Property and equipment, gross	1,120	1,105
Leasehold Improvements [Member]
Property and equipment, gross	4,078	3,985
Construction in Progress [Member]
Property and equipment, gross	$ 191	$ 24

Note 4 - Balance Sheet Compon_7

Note 4 - Balance Sheet Components - Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Intangible assets, gross	$ 5,080	$ 5,080
Less: accumulated amortization	(1,157)	(791)
Intangible assets, net	3,923	4,289
Developed Technology Rights [Member]
Intangible assets, gross	5,000	5,000
Intellectual Property [Member]
Intangible assets, gross	$ 80	$ 80

Note 4 - Balance Sheet Compon_8

Note 4 - Balance Sheet Components - Estimated Future Amortization Expense (Details) $ in Thousands	Jun. 30, 2024 USD ($)
2024 (six months remaining)	$ 365
2025	732
2026	731
2027	731
2028	727
Thereafter	637
Total	$ 3,923

Note 4 - Balance Sheet Compon_9

Note 4 - Balance Sheet Components - Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accrued compensation	$ 3,704	$ 4,576
Accrued clinical and manufacturing expenses	1,591	312
Accrued professional and consulting services	522	211
Other liabilities, current portion	794	535
Total	$ 6,611	$ 5,634

Note 5 - Revenue (Details Textu

Note 5 - Revenue (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Jan. 12, 2024	Nov. 30, 2022
Revenues		$ 6,401,000	$ 1,358,000	$ 8,582,000	$ 2,033,000
Income Tax Expense (Benefit)		21,000	19,000	66,000	48,000
Deferred Revenue, Current							$ 2,000,000
The 2024 ATI-RRPV Contract [Member]
Government Assistance Award, Amount, Initial Award Fixed Fee		64,700,000		64,700,000
The 2024 ATI-RRPV Contract [Member] | Maximum [Member]
Government Assistance, Award Amount		452,900,000		452,900,000
Government Assistance, Award Amount, Initial Award		65,700,000		65,700,000
Government Assistance, Additional Funding Possible		387,200,000		$ 387,200,000
The 2024 ASPR-BARDA Contract [Member]
Government Assistance, Award Amount						$ 9,300,000
Foreign Tax Jurisdiction [Member] | National Tax Agency, Japan [Member]
Royalty Withholding Tax				5%
Income Tax Expense (Benefit)		2,000	1,000	$ 31,000	15,000
Royalty [Member] | Daiichi Sankyo Collaberation and License Agreement [Member]
Royalty Percentage				4%
Non Cash Royalty Revenue [Member]
Revenues		37,000	30,000	$ 622,000	308,000
Non Cash Royalty Revenue [Member] | Daiichi Sankyo Collaberation and License Agreement [Member]
Revenues		37,000	30,000	600,000	300,000
Government Contract [Member]
Revenues		6,364,000	0	7,960,000	0
Government Contract Receivable, Unbilled Amounts		3,700,000		3,700,000
Government Contract [Member] | The 2024 ATI-RRPV Contract [Member]
Revenues		200,000		200,000
Government Contract [Member] | The 2024 ASPR-BARDA Contract [Member]
Revenues		6,200,000		7,800,000
Grant [Member]
Revenues		$ 0	$ 1,328,000	$ 0	$ 1,725,000
Grants Receivable							$ 3,500,000
Grant Milestone Completion [Member]
Revenues	$ 1,500,000

Note 6 - Liabilities Related _3

Note 6 - Liabilities Related to Sale of Future Royalties (Details Textual) - HCRP [Member] - USD ($) $ in Millions	1 Months Ended	6 Months Ended	12 Months Ended
	Apr. 30, 2016	Jun. 30, 2024	Dec. 31, 2023
Proceeds from Sale of Future Royalties, Net	$ 20
Royalty Interest, Covenant, Cumulative Remaining Shortfall Amount		$ 6	$ 7
Royalty Payment, Interest, First Period [Member]
Royalty Interest, Covenant, Shortfall in Royalty Payments	$ 3
Royalty Interest, Percentage of Additional Royalties Due Each Year	15%
Royalty Interest, Additional Royalties Due Each Year	$ 1
Royalty Payment, Interest, Second Period [Member]
Royalty Interest, Covenant, Shortfall in Royalty Payments	$ 2.7
Royalty Interest, Percentage of Additional Royalties Due Each Year	15%
Royalty Interest, Additional Royalties Due Each Year	$ 1

Note 6 - Liabilities Related _4

Note 6 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Current portion	$ (2,686)	$ (3,803)
Long-term portion	1,591	$ 2,623
HealthCare Royalty Partners III, L.P. [Member] | Royalty Arrangement [Member]
Total liability related to sale of future royalties, start of period	6,426
Non-cash royalty revenue paid to HCRP	(3,563)
Non-cash interest expense recognized	1,414
Total liability related to sale of future royalties, end of period	4,277
Current portion	(2,686)
Long-term portion	$ 1,591

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) $ in Thousands	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2021 USD ($)
Operating Lease, Right-of-Use Asset	$ 22,652	$ 24,840
Operating Lease, Weighted Average Discount Rate, Percent	9.80%
Operating Lease, Weighted Average Remaining Lease Term (Year)	4 years 8 months 12 days
Right of Use for Office and Manufacturing Facilities with Initial Terms Exceeding One Year [Member]
Lessee, Operating Lease, Number of Right-of-Use Leases	6
Lease for Facility in South San Francisco Commenced in Third Quarter of 2022 [Member]
Operating Lease, Right-of-Use Asset			$ 15,000
Lease for Facility in South San Francisco Commenced in First Quarter of 2023 [Member]
Operating Lease, Right-of-Use Asset			$ 3,100

Note 7 - Leases - Lease Liabili

Note 7 - Leases - Lease Liabilities Payment Obligations (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
2024 (six months remaining)	$ 2,209
2025	4,511
2026	5,031
2027	5,207
2028	5,389
Thereafter	1,348
Undiscounted total	23,695
Less: imputed interest	(4,840)
Present value of future minimum payments	18,855
Current portion of operating lease liability	(2,872)	$ (2,703)
Operating lease liability, net of current portion	$ 15,983	$ 17,385

Note 7 - Leases - Operating Lea

Note 7 - Leases - Operating Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating lease cost	$ 1,553	$ 1,553	$ 3,107	$ 3,063
Short-term lease cost	7	10	19	31
Variable lease cost	381	431	885	942
Sublease income	(20)	0	(34)	0
Total lease cost	$ 1,921	$ 1,994	$ 3,977	$ 4,036

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	Nov. 02, 2022	Jul. 27, 2022	Jun. 30, 2024
Himmelberg V. Vaxart, Inc. et al. [Member]
Litigation Settlement, Amount Awarded to Other Party		$ 12
Payments for Legal Settlements	$ 2
Lease for Facility in South San Francisco, California [Member]
Purchase Obligation			$ 3.2

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended			3 Months Ended	6 Months Ended
	Aug. 04, 2022	Jun. 30, 2024	Apr. 30, 2024	Jan. 31, 2024	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 11, 2024	Mar. 31, 2024	Dec. 31, 2023
Preferred Stock, Shares Authorized (in shares)		5,000,000			5,000,000	5,000,000				5,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001			$ 0.0001	$ 0.0001				$ 0.0001
Preferred Stock, Shares Outstanding, Ending Balance (in shares)		0			0	0				0
Common Stock, Shares Authorized (in shares)		350,000,000			350,000,000	350,000,000		350,000,000	250,000,000	250,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001			$ 0.0001	$ 0.0001				$ 0.0001
Common Stock, Increase in Shares Authorized (in shares)	100,000,000
Dividends, Total						$ 0
Treasury Stock, Common, Shares (in shares)		688,331			688,331	688,331				507,020
Class of Warrant or Right, Expirations in Period (in shares)			70,663
Warrants Expiring March 2025 [Member]
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		$ 2.5			$ 2.5	$ 2.5
Warrants Expiring February 2025 [Member]
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		$ 3.125			3.125	3.125
June 2024 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		50,000,000
Shares Issued, Price Per Share (in dollars per share)		$ 0.8			$ 0.8	$ 0.8
Stock Issued During Period, Value, New Issues		$ 40,000			$ 37,555	$ 37,555
Proceeds from Issuance of Common Stock		$ 37,600				37,555	$ 0
RA Capital Healthcare Fund 2024 [Member]
Stock Issued During Period, Shares, New Issues (in shares)				15,384,615
Shares Issued, Price Per Share (in dollars per share)				$ 0.65
Stock Issued During Period, Value, New Issues					$ 0	9,945
Proceeds from Issuance of Common Stock				$ 9,900		$ 9,945	$ 0
Gross Proceeds from Issuance of Common Stock				$ 10,000

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details) - shares	Jun. 30, 2024	Feb. 27, 2024	Dec. 31, 2023
Common stock reserved for issuance (in shares)	45,688,228		27,043,664
Common Warrants [Member]
Common stock reserved for issuance (in shares)	140,596		227,434
The 2019 Plan [Member]
Common stock reserved for issuance (in shares)	16,621,469		5,685,806
The 2024 Inducement Award Plan [Member]
Common stock reserved for issuance (in shares)	1,727,500	3,000,000	0
Share-Based Payment Arrangement, Option [Member]
Common stock reserved for issuance (in shares)	21,699,803		17,938,726
Restricted Stock Units (RSUs) [Member]
Common stock reserved for issuance (in shares)	3,135,958		2,126,373
ESPP [Member]
Common stock reserved for issuance (in shares)	2,362,902		1,065,325

Note 9 - Stockholders' Equity_3

Note 9 - Stockholders' Equity - Summary of Warrants Outstanding (Details)	Jun. 30, 2024 $ / shares shares
Securities into which warrants are convertible (in shares)	140,596
First Set of Warrants Expiring April 2024 [Member]
Securities into which warrants are convertible (in shares)	29,150
Securities into which warrants are convertible (in dollars per share) | $ / shares	$ 2.5
Second Set of Warrants Expiring April 2024 [Member]
Securities into which warrants are convertible (in shares)	100,532
Securities into which warrants are convertible (in dollars per share) | $ / shares	$ 3.125
Warrants Expiring March 2025 [Member]
Securities into which warrants are convertible (in shares)	10,914
Securities into which warrants are convertible (in dollars per share) | $ / shares	$ 22.99

Note 10 - Equity Incentive Pl_3

Note 10 - Equity Incentive Plans (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 28, 2024	Jun. 11, 2024	May 31, 2024	Feb. 27, 2024	Dec. 31, 2023	Nov. 30, 2023	May 31, 2023	Aug. 04, 2022	Jun. 16, 2021	Jun. 08, 2020	Apr. 23, 2019
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	45,688,228						27,043,664
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	21,699,803						17,938,726
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 2.5						$ 2.9
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	7 years 1 month 2 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$ 35,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number (in shares)	12,175,103
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 2.98
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)	5 years 6 months 18 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$ 35,000
Proceeds from Stock Options Exercised	$ 21,000	$ 17,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)	26,980	54,720
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 6,000	$ 31,000
Share Price (in dollars per share)			$ 0.67
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 1.01	$ 0.78
Proceeds from Stock Plans	$ 312,000	$ 298,000
Options and RSU [Member]
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 18,700,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years 4 months 24 days
The 2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				43,900,000						28,900,000	16,900,000	8,000,000	1,600,000
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	16,621,469						5,685,806
The 2024 Inducement Award Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	1,727,500					3,000,000	0
The 2022 ESPP [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	2,362,902			3,600,000						1,800,000
Share Price (in dollars per share)					$ 0.27			$ 0.54	$ 0.46
Proceeds from Stock Plans	$ 300,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)	502,423
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 0

Note 10 - Equity Incentive Pl_4

Note 10 - Equity Incentive Plans - Summary of Stock Option Transactions (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2024	Jun. 30, 2023
Shares available for grant, balance (in shares)		5,685,806	5,685,806
Number of options outstanding, beginning balance (in shares)		17,938,726	17,938,726
Weighted average exercise price, balance (in dollars per share)		$ 2.9	$ 2.9
Shares available for grant, granted (in shares)			(7,135,230)
Number of options outstanding, granted (in shares)			5,226,937
Weighted average exercise price, granted (in dollars per share)			$ 1.12
Number of options outstanding, exercised (in shares)			(26,980)	(54,720)
Weighted average exercise price, exercised (in dollars per share)			$ 0.78
Number of RSUs outstanding, release (in shares)			(526,424)
Released, Weighted average grant date fair value (in dollars per share)		$ 1.39
Shares available for grant, forfeited (in shares)			1,659,141
Number of options outstanding, forfeited (in shares)			(1,286,857)
Weighted average exercise price, forfeited (in dollars per share)			$ 2.2
Shares available for grant, canceled (in shares)			139,252
Number of options outstanding, canceled (in shares)			(152,023)
Weighted average exercise price, canceled (in dollars per share)			$ 5.2
Shares available for grant, balance (in shares)	18,348,969		18,348,969
Number of options outstanding, balance (in shares)	21,699,803		21,699,803
Weighted average exercise price, balance (in dollars per share)	$ 2.5		$ 2.5
The 2024 Inducement Award Plan [Member]
Authorized (in shares)			3,000,000
The 2019 Plan [Member]
Authorized (in shares)			15,000,000
Restricted Stock Units (RSUs) [Member]
Number of RSUs outstanding (in shares)		2,126,373	2,126,373
Balance, Weighted average grant date fair value (in dollars per share)	$ 1.21	$ 1.37	$ 1.37
Number of RSUs outstanding, granted (in shares)			1,908,293
Granted, Weighted average grant date fair value (in dollars per share)		1.14
Number of RSUs outstanding, forfeite (in shares)			(372,284)
Forfeited, Weighted average grant date fair value (in dollars per share)		1.49
Number of RSUs outstanding (in shares)	3,135,958		3,135,958
Balance, Weighted average grant date fair value (in dollars per share)		$ 1.21

Note 10 - Equity Incentive Pl_5

Note 10 - Equity Incentive Plans - Assumptions of Options (Details) - Share-Based Payment Arrangement, Option [Member]	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Risk-free interest rate	4.40%
Expected term (in years) (Year)	6 years	6 years
Minimum [Member]
Risk-free interest rate		3.50%
Expected volatility	128.90%	127.80%
Maximum [Member]
Risk-free interest rate		3.90%
Expected volatility	129.30%	129.50%

Note 10 - Equity Incentive Pl_6

Note 10 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Stock-based compensation	$ 2,555	$ 3,927	$ 6,671	$ 6,574
Research and Development Expense [Member]
Stock-based compensation	1,868	2,366	3,675	3,738
General and Administrative Expense [Member]
Stock-based compensation	$ 687	$ 1,561	$ 2,996	$ 2,836

Note 10 - Equity Incentive Pl_7

Note 10 - Equity Incentive Plans - Assumptions of Employee Purchase Plan (Details) - The 2022 ESPP [Member]	6 Months Ended
	May 31, 2024	Nov. 30, 2023	May 31, 2023
Risk-free interest rate	5.30%	5.40%	4.60%
Expected term (in years) (Year)	6 months	6 months	6 months
Expected volatility	75.20%	98.60%	84.70%
Dividend yield	0%	0%	0%

Note 11 - Net Loss Per Share _3

Note 11 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net loss	$ (16,466)	$ (22,550)	$ (40,883)	$ (47,690)
Shares used to compute net loss per share - basic and diluted (in shares)	184,703,003	139,594,238	176,757,049	137,403,416
Net loss per share - basic and diluted (in dollars per share)	$ (0.09)	$ (0.16)	$ (0.23)	$ (0.35)

Note 11 - Net Loss Per Share _4

Note 11 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	25,069,727	22,738,219	22,882,059	19,526,614
Share-Based Payment Arrangement, Option [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	21,705,187	18,469,856	19,869,813	16,452,951
Restricted Stock Units (RSUs) [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	3,223,944	3,672,594	2,600,499	2,445,397
Warrant [Member] | Common Stock [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	140,596	227,434	175,928	227,434
Employee Stock Purchase Plan [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	0	368,335	235,819	400,832